Shree Ganesh Remedies Reports Q1FY27 Results Amid Subdued European Demand
Shree Ganesh Remedies Limited, a fast-growing CMO and CDMO based in India specializing in Pharmaceutical Intermediates and Fine Chemicals, announced its unaudited financial results for the quarter ended June 30, 2026. The company reported revenue of 14.36 Cr., while profitability metrics reflected challenging market dynamics, particularly in Europe.The company detailed a total income of 15.30 Cr. and earned an EBITDA of 3.35 Cr. for the quarter, marking a 23.3% EBITDA margin. Profit after tax (PAT) stood at 1.12 Cr., a significant decline reported against prior periods.
Financial Performance Summary
Financial analysis for Q1FY27 shows a material dip compared to previous quarters. The company generated 11.49 Cr. from Pharma Intermediates and 2.88 Cr. from Speciality Chemicals. Export revenue totaled 8.64 Cr.The following table provides a detailed comparison of key financial indicators across Q1FY26, Q4FY26, and Q1FY27:
| PARTICULARS (₹ IN CRORES) | Q1FY26 | Q4FY26 | Q1FY27 | YoY Change | QoQ Change |
|---|---|---|---|---|---|
| Revenue from Operations | 24.67 | 33.20 | 14.36 | -42% | -57% |
| Total Income | 25.33 | 34.22 | 15.30 | -40% | -55% |
| Operating Expenses | 17.37 | 21.87 | 11.01 | -37% | -50% |
| EBITDA (Excluding OI & EI) | 7.30 | 11.37 | 3.35 | -54% | -71% |
| EBITDA % | 29.6% | 34.3% | 23.3% | -624 bps | -1,092 bps |
| Finance Cost | 0.94 | 0.88 | 0.32 | -66% | -64% |
| Depreciation & Ammortization | 2.42 | 2.80 | 2.44 | 1% | -13% |
| PBT | 4.60 | 8.72 | 1.53 | -67% | -82% |
| PAT | 3.45 | 6.27 | 1.12 | -68% | -82% |
| EPS (₹) | 2.69 | 4.88 | 0.87 | -68% | -82% |
Management Commentary and Outlook
Gunjan Kothia, Promoter, commented on the results, noting that Q1FY27 presented a challenging quarter for the Company. Subdued demand from Europe, coupled with geopolitical uncertainty and volatility in raw material markets, directly impacted the company’s topline and profitability. This softer demand environment has been observed extending into the early part of Q2FY27.A key operational development was the automatic termination of the marketing and manufacturing agreement with one EU distributor due to non-performance against agreed commercial terms. Kothia stated that this transition allows Shree Ganesh Remedies to engage directly with customers, giving the company greater control over these relationships. The management anticipates that it will take a couple of quarters before volumes are meaningfully restored, but they remain confident in returning to prior run-rate levels in the second half of the financial year.
Regarding growth pipelines, engagements under CRAMS in South-East Asia continue progressing on schedule, with projects anticipated to contribute revenue starting from H2FY27.
Given the unexpected persistence of geopolitical headwinds and customer caution, Kothia stated that the company finds it appropriate to moderate its earlier guidance for FY27. While the CRAMS pipeline and Block 7 are still proceeding towards commissioning, the strategic direction of the business has not changed. The management views the current situation as a timing issue and expressed confidence that the second half of FY27 will reflect meaningful performance improvement as various catalysts come online.
Shree Ganesh Remedies Limited, which serves over 20 countries including key markets in the EU and the US, remains committed to disciplined execution on strategic priorities for sustainable medium-to-long-term growth.
Stock Price Movement
At 12:35, shares of Shree Ganesh Remedies Ltd are ticking lower, currently standing at ₹552.35, which represents a 9.46% drop. Throughout the trading session, the stock has fluctuated significantly within an intraday range spanning from ₹501.50 to a high of ₹559.70.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.